Changeflow GovPing Courts & Legal USPTO Guidance on Best Practices for Subject Ma...
Priority review Guidance Amended Final

USPTO Guidance on Best Practices for Subject Matter Eligibility Declarations

Favicon for www.uspto.gov USPTO Subject Matter Eligibility (101)
Published December 4th, 2025
Detected March 22nd, 2026
Email

Summary

The USPTO issued guidance on best practices for submitting Subject Matter Eligibility Declarations (SMEDs) under 37 CFR 1.132. The guidance encourages applicants to submit SMEDs as separate documents, distinct from declarations addressing other issues like obviousness, to clarify evidence relevant to patent eligibility under 35 U.S.C. § 101.

What changed

This memorandum from the USPTO Director clarifies best practices for submitting Subject Matter Eligibility Declarations (SMEDs) under 37 CFR 1.132. It emphasizes that SMEDs should be filed as separate documents, distinct from declarations addressing other patentability issues such as obviousness or secondary considerations. The guidance reiterates that SMEDs are intended to provide objective evidence specifically relevant to the eligibility of the claimed invention under 35 U.S.C. § 101, and that combining them with other testimony may complicate examiner analysis and diminish the probative value of the evidence.

Patent applicants and practitioners are encouraged to follow these best practices to ensure clarity and effectiveness when responding to subject matter eligibility rejections. The USPTO has also distributed a memorandum to its Examining Corps reminding them of the voluntary submission of SMEDs under Rule 132. Failure to properly structure these declarations could lead to confusion regarding the evidentiary weight and relevance of the testimony, potentially impacting the examiner's evaluation of the claimed invention's patent eligibility.

What to do next

  1. Submit Subject Matter Eligibility Declarations (SMEDs) as separate documents.
  2. Ensure SMEDs address only subject matter eligibility (35 U.S.C. § 101) and are distinct from declarations on obviousness or other issues.
  3. Review USPTO MPEP sections 716, 2106, and 2145 for guidance on declaration relevance and content.

Source document (simplified)

MEMORANDUM ,l,,les~

To: All Patent Applicants an Patent Practitioners John A. Squire _ _From: Under Secretar o co ln~ ~ 9, ~ or Intellectual Property and Director of the United States Patent and Trademark Office Subject: Best Practices for Submission of Rule 132 Subject Matter Eligibility Declarations (SMEDs) Date: December 4, 2025

  1. Introduction
    This memorandum addresses the best practice for submitting Subject Matter Eligibility Declarations (SMEDs) under 37 CFR 1.132 to address subject matter eligibility (SME) rejections in U.S. patent prosecution. Specifically, it supports the proposition that SMEDs should be submitted as separate documents and not combined with declarations or testimony addressing other issues, such as obviousness (e.g., secondaiy considerations or motivation to combine). Further, attached as Appendix A is a memorandum distributed to the USPTO Examining Corps, to ale11 (and remind) the Examiners that applicants voluntarily may submit which is intended SMEDs pursuant to existing Rule 132 (SMED Examiner Memo).

  2. USPTO Guidance and Rationale

  3. SMEDs and Subject Matter Eligibility
    The SMED Examiner Memo highlights the unique evidentiary role of SMEDs in addressing SME rejections. SMEDs are intended to clarify the record and provide objective evidence specifically relevant to the eligibility of the claimed invention under 35 U.S.C. § 101. The SMED Examiner Memo states: "For an evidentiary declaration to be relevant, there must be a nexus between the invention as claimed and the evidence provided in the declaration .... a SMED

may demonstrate how one of ordinary skill in the art would interpret a specification that describes a technological improvement to show that the claimed invention is patent -e ligible subject matter." 1

The SMED Examiner Memo further emphasizes that SMEDs must not improperly supplement the specification and must be timely filed, with a clear nexus to the claimed invention.

  1. Risks of Combining SMEDs with Other Testimony Though it is permissible to file a single declaration under 3 7 CFR 1.132 addressing rejections under multiple statutory requirements, applicants are encouraged to submit a separate SMED to address subject matter eligibility. By providing testimony and objective evidence directed solely to the SME of the claimed invention, the applicant may avoid the risk of intertwining issues of enablement, written description, novelty and nonobviousness with those of subject matter eligibility. The USPTO's Manual of Patent Examining Procedure (MPEP) provides separate guidance for declarations addressing SME (§ 101) and those addressing obviousness (§ 103):
  • MPEP 716: Declarations under Rule 132 must be relevant to the specific rejection
    traversed.

  • MPEP 2106: Declarations can be submitted to provide evidence traversing a subject
    matter eligibility rejection under 35 U.S.C. 101. See MPEP 2106.07(b). For example, in response to a subject matter eligibility rejection, a declaration can be submitted to provide testimony on how one of ordinary skill in the art would interpret the disclosed invention as improving technology and the underlying factual basis for that conclusion. See MPEP 2106.0S(a).

  • MPEP 2145: Declarations for obviousness may address secondaiy considerations and
    motivation to combine, which are distinct from SME issues. Combining these can lead to confusion regarding the evidentiaiy weight and relevance of the testimony, and may complicate the examiner's analysis and the applicant's record.

  1. Examiner Consideration The SMED Examiner Memo instructs examiners to: "carefully consider all of the applicant's arguments and the evidence rebutting the subject matter eligibility rejection when evaluating the applicant's response."

As noted above, if a SMED is combined with other, non-SME testimony, the examiner may have difficulty isolating the evidence relevant to SME, potentially diminishing the probative value of the SMED and complicating the Office action. Moreover, MPEP 716.0l(d) provides additional information relating to examiner consideration when an applicant timely submits evidence traversing a rejection.

  1. Third-Party and USPTO Guidance
  2. USPTO Training Materials

USPTO training materials and job aids treat declarations for SME and obviousness as distinct submissions. For example:

  • USPTO Entry Level and Training for Experienced Examiner (TEE) Training: Declaration Practice Under 37 CFR 1.132: Recommends declarations be tailored to the

specific rejection traversed.

TC 1600 Job Aid on Evidence of Unexpected Results Under 37 CFR 1.132: Focuses •

solely on obviousness, not SME.

  1. Federal Circuit Case Law

Federal Circuit decisions reinforce the need for clear, focused evidentimy records:

  • In re Oetiker, 977 F.2d 1443 (Fed. Cir. 1992): The burden of proof shifts depending on
    the rejection, and evidence must be relevant to the specific issue.

  • In re Sullivan, 498 F.3d 1345 (Fed. Cir. 2007): The Board must consider all evidence
    submitted, including multiple declarations, and may not disregard any simply because they address different aspects of patentability.

  1. Practitioner Guidance

Patent practitioners routinely advise submitting separate declarations for SME and obviousness. For example:

  • AIPLA Practice Guide: Declarations should be responsive to the specific grounds of
    rejection they seek to overcome and should avoid combining arguments or evidence directed to different statutory requirements in a single declaration. 3

  • Fish & Richardson, "Best Practices for Rule 132 Declarations": When addressing
    multiple statutory issues (e.g., § 101 eligibility and§ 103 obviousness), consider using separate Rule 132 declarations. This approach improves clarity, avoids confusion, and ensures that each declaration is focused on the specific rejection being traversed.

  1. Conclusion Based on USPTO guidance, Federal Circuit precedent, and practitioner best practices, SMEDs addressing subject matter eligibility under Rule 132 should be submitted as separate documents and not combined with testimony on other issues such as obviousness. This approach:
  • Ensures clarity and relevance of the evidentiaiy record.
  • Facilitates examiner review and decision-making.
  • Enhances the clarity and may bolster probative value of the SMED.
  • Reduces risk of procedural or substantive confusion.
    References:

  • USPTO SMED Memorandum to the Examining Corps, December 4, 2025 (attached as
    Appendix A)

  • MPEP 716, 2106.05(a), 2145

  • In re Oetiker, 977 F.2d 1443 (Fed. Cir. 1992)

  • In re Sullivan, 498 F.3d 1345 (Fed. Cir. 2007)

  • AIPLA Practice Guide

  • Fish & Richardson, "Best Practices for Rule 132 Declarations"

  • USPTO TEE Training Materials

    # #

Appendix A (USPTO Memorandum to Examiners on Subject Matter Eligibility Declarations)

CFR references

37 CFR 1.132

Named provisions

Introduction USPTO Guidance and Rationale SMEDs and Subject Matter Eligibility Risks of Combining SMEDs with Other Testimony Examiner Consideration

Classification

Agency
USPTO
Published
December 4th, 2025
Instrument
Guidance
Legal weight
Non-binding
Stage
Final
Change scope
Substantive
Document ID
USPTO Subject Matter Eligibility (101)

Who this affects

Applies to
Legal professionals
Industry sector
5411 Legal Services
Activity scope
Patent Prosecution
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Patent Prosecution Evidence

Get Courts & Legal alerts

Weekly digest. AI-summarized, no noise.

Free. Unsubscribe anytime.

Get alerts for this source

We'll email you when USPTO Subject Matter Eligibility (101) publishes new changes.

Free. Unsubscribe anytime.